Methods for isolating circulating epithelial cells and criteria for their classification as carcinoma cells

被引:109
作者
Fehm, T
Solomayer, EF
Meng, S
Tucker, T
Lane, N
Wang, J
Gebauer, G
机构
[1] Univ Tubingen, Dept Obstet & Gynecol, D-72076 Tubingen, Germany
[2] UT SW Med Ctr, Ctr Canc Immunobiol, Dallas, TX USA
[3] Heidelberg Univ, Dept Gynecol & Obstet, Hannover, Germany
关键词
circulating tumor cell; FISH; genotyping; immunomagnetic enrichment; immunophenotyping;
D O I
10.1080/14653240510027082
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Novel assay methods developed for the isolation and characterization of circulating tumor cells (CTC) of epithelial origin offer the potential of markers for the non-invasive gathering of clinical information relevant to the diagnosis, evolution and treatment of carcinoma. Of the numerous techniques currently used to analyze CTC, slide-based assays are perhaps the most common. While traditional combined immunocytochemical/brightfield microscopy systems continue to be the most frequently employed, fluorescence-based analysis is gaining in importance. This is partly because fluorescence microscopy analysis of slide-mounted CTC can provide simultaneously cytogenetic as well as morphologic and multiple phenotypic information. In particular, fluorescence microscopy analysis of slide-mounted CTC can accurately determine genetic changes at the chromosomal level in patients with recurrent disease. More importantly, by identifying genetic aberrations in CTC, it becomes possible to choose those patients most likely to benefit from a given treatment. The potential of this technique has already been demonstrated by employing fluorescence in situ hybridization (FISH) methods to measure expression of the HER2/neu gene in tissue from patients with breast carcinoma for the specific purpose of identifying those patients most likely to respond to Trastuzumab targeted therapy. Here, we review the major methodologies used in the preparation and analysis of the slide-based assays.
引用
收藏
页码:171 / 185
页数:15
相关论文
共 68 条
[1]   Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells [J].
Borgen, E ;
Naume, B ;
Nesland, JM ;
Kvalheim, G ;
Beiske, K ;
Fodstad, O ;
Diel, I ;
Solomayer, EF ;
Theocharous, P ;
Coombes, RC ;
Smith, BM ;
Wunder, E ;
Marolleau, JP ;
Garcia, J ;
Pantel, K .
CYTOTHERAPY, 1999, 1 (05) :377-388
[2]   Use of automated microscopy for the detection of disseminated tumor cells in bone marrow samples [J].
Borgen, E ;
Naume, B ;
Nesland, JM ;
Nowels, KW ;
Pavlak, N ;
Ravkin, I ;
Goldbard, S .
CYTOMETRY, 2001, 46 (04) :215-221
[3]  
Borgen E, 1998, J PATHOL, V185, P427, DOI 10.1002/(SICI)1096-9896(199808)185:4<427::AID-PATH127>3.0.CO
[4]  
2-7
[5]  
Brandt B, 1996, CANCER RES, V56, P4556
[6]   A relevant Immunomagnetic assay to detect and characterize epithelial cell adhesion molecule-positive cells in bone marrow from patients with breast carcinoma - Immunomagnetic purification of micrometastases [J].
Choesmel, V ;
Anract, P ;
Hoifodt, H ;
Thiery, JP ;
Blin, N .
CANCER, 2004, 101 (04) :693-703
[7]   Circulating tumor cells, disease progression, and survival in metastatic breast cancer [J].
Cristofanilli, M ;
Budd, GT ;
Ellis, MJ ;
Stopeck, A ;
Matera, J ;
Miller, MC ;
Reuben, JM ;
Doyle, GV ;
Allard, WJ ;
Terstappen, LWMM ;
Hayes, DF .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (08) :781-791
[8]  
DOYLE GV, 2004, ANN M P ASCO, V23, P841
[9]  
Fehm T, 2002, CLIN CANCER RES, V8, P2073
[10]  
FEHM T, 2002, BREAST CANC RES TREA, V2379, P1